

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Snell Kristi</u>	2. Date of Event Requiring Statement (Month/Day/Year) 10/17/2016	3. Issuer Name and Ticker or Trading Symbol <u>METABOLIX, INC. [MBLX]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>VP Research & CSO</u>	5. If Amendment, Date of Original Filed (Month/Day/Year)
(Last) (First) (Middle) <u>C/O METABOLIX, INC.</u> <u>19 PRESIDENTIAL WAY</u>			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person
(Street) <u>WOBURN MA 01801</u>			
(City) (State) (Zip)			

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	18,208	D	
Common Stock	23,700	I	By 401(k) Plan ⁽¹⁾
Common Stock	43,749 ⁽⁶⁾	D	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (right to buy)	(2)	03/05/2018	Common Stock	417	90	D	
Stock Option (right to buy)	(2)	05/30/2018	Common Stock	2,500	67.32	D	
Stock Option (right to buy)	(2)	10/21/2018	Common Stock	1,400	54.72	D	
Stock Option (right to buy)	(2)	08/21/2019	Common Stock	1,333	63.24	D	
Stock Option (right to buy)	(2)	02/12/2020	Common Stock	1,667	58.62	D	
Stock Option (right to buy)	(2)	02/11/2021	Common Stock	1,667	54.72	D	
Stock Option (right to buy)	(2)	02/01/2022	Common Stock	3,334	15.96	D	
Stock Option (right to buy)	(2)	05/31/2022	Common Stock	3,334	12	D	
Stock Option (right to buy)	(2)	09/18/2022	Common Stock	10,000	9.3	D	
Stock Option (right to buy)	(3)	02/13/2023	Common Stock	1,667	10.08	D	
Stock Option (right to buy)	(4)	07/22/2023	Common Stock	4,167	8.88	D	
Stock Option (right to buy)	(5)	02/24/2024	Common Stock	5,001	7.74	D	

Explanation of Responses:

- Shares acquired as Company matching contributions under the Metabolix, Inc. 401(k) Plan.
- This option is fully vested and exercisable.
- This option vests and becomes exercisable in 16 equal quarterly installments over a period of 4 years from 2/13/13.
- This option vests and becomes exercisable in 16 equal quarterly installments over a period of 4 years from 7/22/13.
- This option vests and becomes exercisable in 16 equal quarterly installments over a period of 4 years from 2/24/14.
- These securities are in the form of restricted stock units ("RSUs") issued under the Issuer's 2014 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in three equal annual installments on 4/1/17, 4/1/18 and 4/1/19. All RSUs that have not vested will terminate upon the reporting person's termination of employment with the Issuer and its subsidiaries.

/s/ Sarah P. Cecil, attorney-in-fact 10/26/2016

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Sarah P. Cecil, Charles B. Haaser, John M. Mutkoski, and any one of them acting singly, the true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for the undersigned and in the undersigned's name, place and stead, in any and all capacities (until revoked in writing) to execute for and on behalf of the undersigned, in any and all of the undersigned's capacities, any and all statements on Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by Metabolix, Inc. (the "Company") in accordance with Sections 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and any and all regulations promulgated thereunder, and to file the same, with all exhibits thereto, and any other documents in connection therewith, with the Securities and Exchange Commission, and with any other entity when and if such is mandated by the Exchange Act or by the By-laws of the National Association of Securities Dealers, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary fully to all intents and purposes as the undersigned might or could do in person thereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, this Power of Attorney has been signed as of October 24, 2017.

Signature: /s/ Kristi Snell
Name: Kristi Snell